China Paddy and Rice Processing Industry Report, 2011-2012

China’s paddy and rice processing enterprises vary in profitability due to different operating modes and products. Enterprises in the fifth mode represented by Wanfu Biotechnology feature higher profitability since their rice resources are developed comprehensively and utilized sufficiently, and their products are involved in the whole industry chain. From January to September of 2011, Wanfu Biotechnology’s operating revenue and net income were RMB396 million and RMB51.09 million respectively, increasing 25.7% and 37.6% separately year on year. In 2011, the company went public to raise funds in order to expand its production capacity of major products. Its production capacity is expected to be doubled after the capacity expansion project being put into production.

In consideration of Wanfu Biotechnology’s first-mover advantage, enterprises represented by Yihai Kerry Group and COFCO Rice Division depend on their scale advantage as well as existing brands and channels to set foot in the paddy and rice processing industry. Such enterprises are dominant producers of small packing polished rice, while the sales volume of small packing polished rice accounts for less than 10% of the rice consumption in China at present. As people pay more and more attention to the nutritional and healthcare function of rice, these enterprises will see a promising market development prospect. However, Beidahuang and Jinjian, also being producers of small packing polished rice, have relatively low profitability due to regional and production scale restrictions.

China Paddy & Rice Processing Market

Published: March 2012
No. of Pages: 51
Price: Single User License – US$1600              Corporate User License – US$2400


                       


Representative enterprises in the third mode and the fourth mode, such as Shanghai Rong Xuan Hang and Wuhan Jiabao, only focus on the development of rice albumen powder, rice starch sugar and the like in the industry chain. In spite of small number of product categories, they also see huge development potential owing to relatively higher technical barriers and prosperous market demand. Taking rice starch sugar product as an example, it is gradually replacing cane sugar featured with insufficient quantity and high price due to its low cost and sufficient raw materials; and its output is expected to reach 1.7 million tons in 2013 in China, and its proportion in the total output of starch sugar will rise to 14.2% from 12.8% in 2006.

China Paddy and Rice Processing Industry Report, 2011-2012 mainly covers the followings:
• Development environment, industry scale and development trend of paddy and rice processing industry in China
• Supply and demand of upstream raw materials and downstream deep processing products in Chinese paddy and rice processing industry
• Major operating modes of paddy and rice processing enterprises in China and development of representative enterprises, comprising overall operation, production capacity, output and development strategies, etc.
• Forecast of the development trend of paddy & rice processing companies and the whole Chinese paddy and rice processing industry

Major points covered in Table of Contents of this report include:
1. Overview of Paddy and Rice Processing Industry
2. Supply and Demand of Paddy and Rice Processing Industry
3. Characteristics of Paddy and Rice Processing Industry in China
4. Key Enterprises
5. Summary and Forecast
List of Charts

Browse reports related to Biotechnology @ http://www.reportsnreports.com/market-research/biotechnology/

Molecular Diagnostics: Market Landscape

This report Molecular Diagnostics: Market Landscape analyzes the emerging sector of molecular diagnostics. It provides a clear classification, assessing the leading technologies and key tests that are positioned in this exciting area of diagnostics. The current MDx market size and leading players are analyzed, with a market forecast of the MDx segment as well as the total in vitro diagnostic market over 2010-16 provided.

Table Of Contents

ABOUT DATAMONITIOR HEALTHCARE
About the PharmaVitae Company Analysis team

ABOUT THIS REPORT
Chapter structure
Classification of molecular diagnostics
Regulation and reimbursement of molecular diagnostics
The molecular diagnostics market

EXECUTIVE SUMMARY
Strategic scoping and focus
Datamonitor key findings

CLASSIFICATION OF MOLECULAR DIAGNOSTICS
Key findings
Datamonitor’s classification of molecular diagnostics
Level 1 classification
Level 2 classification
Level 3 classification
Level 4 classification
MDx subclassification
Key applications of pharmacogenetics – introducing "personalized medicine"

REGULATION AND REIMBURSEMENT OF MOLECULAR DIAGNOSTICS
Key findings
Regulatory landscape
The FDA operates a risk-based assessment
CLIA – regulation of clinical laboratories through the CMS
Four strategic routes to approval of a diagnostic test in the US
The EU: a more simplified approach – gaining the CE mark
The diagnostics market is much smaller than the prescription pharmaceutical market…
…although it can offer some attractions to investors
However, some hurdles exist
Challenges facing the molecular diagnostics industry: US reimbursement
Challenges facing the MDx industry: intellectual property

THE MOLECULAR DIAGNOSTICS MARKET
Key findings
Introduction
The global in vitro diagnostic and molecular diagnostic markets
Historical IVD and molecular diagnostic performance, 2004–10
Current market leaders: introduction to the key players
Forecast IVD and MDx performance, 2010–16
Overview of US-approved molecular diagnostics tests

APPENDIX
The key technologies
Table of US-approved/cleared molecular diagnostic tests
References
Exchange rates